Angel wins American life sciences contract
Under the initial deal, Angel will use its Cramlington site to make an ingredient for one of the American firm’s products. If the production process is a success then Angel will win a further contract to ramp up output.
Richard Cooper, chief scientific officer at TransGenRx, said: “The development and production of this interferon product is key to the future of TransGenRx, hence the reason we have entrusted its delivery to the team at Angel.
“We are confident this will be the first of a number of projects that we would like to progress with Angel”.